Neovasc to Report Fourth Quarter and Fiscal Year 2020 Results on March 11, 2021
March 04 2021 - 8:00AM
via NewMediaWire -- Neovasc, Inc. (NASDAQ, TSX: NVCN)
will report results for the fourth quarter and fiscal year ended
December 31, 2020 after the market close on Thursday, March 11,
2021. Neovasc President and Chief Executive Officer Fred
Colen and Chief Financial Officer Chris Clark will host a
conference call to review the Company’s results at 4:30 pm EST.
Interested parties may access the conference call by dialing
(877) 407-9208 or (201) 493-6784 (International).
Participants wishing to join the call via webcast should use the
link posted on the investor relations section of the Neovasc
website at https://www.neovasc.com/investors/.
A replay of the webcast will be available approximately 30
minutes after the conclusion of the call using the link on the
Neovasc website.
About Neovasc Inc.
Neovasc is a specialty medical device company that
develops, manufactures and markets products for the rapidly growing
cardiovascular marketplace. The Company is a leader in the
development of minimally invasive transcatheter mitral valve
replacement technologies, and minimally invasive devices for the
treatment of refractory angina. Its products include the Neovasc
Reducer™, for the treatment of refractory angina, which is not
currently commercially available in the United States (2 U.S.
patients have been treated under Compassionate Use) and has been
commercially available in Europe since 2015, and Tiara™, for the
transcatheter treatment of mitral valve disease, which is currently
under clinical investigation in the United States, Canada, Israel
and Europe. For more information, visit: www.neovasc.com.
Investors
Mike Cavanaugh
Westwicke/ICR
Phone: +1.646.877.9641
Mike.Cavanaugh@westwicke.com
Media
Sean Leous
Westwicke/ICR
Phone: +1.646.677.1839
Sean.Leous@icrinc.com
Forward-Looking Statement Disclaimer
Certain statements in this news release contain forward-looking
statements within the meaning of the U.S. Private Securities
Litigation Reform Act of 1995 and applicable Canadian securities
laws that may not be based on historical fact. When used
herein, the words "expect", "anticipate", "estimate", "may",
"will", "should", "intend," "believe", and similar expressions, are
intended to identify forward-looking statements.
Forward-looking statements may involve, but are not limited to the
expansion of its product range and the growing cardiovascular
marketplace. Forward-looking statements are based on estimates and
assumptions made by the Company in light of its experience and its
perception of historical trends, current conditions and expected
future developments, as well as other factors that the Company
believes are appropriate in the circumstances. Many factors
could cause the Company's actual results, performance or
achievements to differ materially from those expressed or implied
by the forward-looking statements, including those described in the
"Risk Factors" section of the Company's Annual Report on Form 20-F
and in the Management's Discussion and Analysis for the three and
nine months ended September 30, 2020 (copies of which may be
obtained at www.sedar.com or www.sec.gov).
These factors should be considered carefully, and readers should
not place undue reliance on the Company's forward-looking
statements. The Company has no intention and undertakes no
obligation to update or revise any forward-looking statements,
whether as a result of new information, future events or
otherwise.
Neovasc (NASDAQ:NVCN)
Historical Stock Chart
From Apr 2024 to May 2024
Neovasc (NASDAQ:NVCN)
Historical Stock Chart
From May 2023 to May 2024